论文部分内容阅读
本文要点HDI是药物定量很好的仪器,可以给患者提供个性化的药物治疗。有必要针对基因型来对哮喘患者进行个性化治疗以达到最佳的治疗效果。吸入性糖皮质激素是对顽固性哮喘患儿首选的一线维持性治疗药物。对哮喘的治疗还应包括对过敏性鼻炎等并发症的处理。盘对环境致敏原敏感性的识别、对家庭环境暴露(致敏原和非特异性刺激物)的评估以及对患者的教育等都是哮喘治疗的重要方面。
Key points of this article HDI is a well-quantified instrument that provides patients with personalized medication. It is necessary to personalize the treatment of asthmatics for the genotype to achieve the best therapeutic outcome. Inhaled glucocorticoids are the first-line maintenance therapies for children with refractory asthma. The treatment of asthma should also include the treatment of complications such as allergic rhinitis. Discrimination of plate sensitivity to environmental allergens, assessment of household environmental exposures (allergens and nonspecific stimuli), and patient education are all important aspects of asthma treatment.